Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
&NA;
1997.
Clozapine.
Reactions Weekly,
Vol. &NA;,
Issue. 662,
p.
7.
Carvajal, Alfonso
and
Martín Arias, Luis H.
1999.
Vol. 22,
Issue. ,
p.
45.
Tollefson, Gary D.
and
Taylor, Cindy C.
2000.
Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent.
CNS Drug Reviews,
Vol. 6,
Issue. 4,
p.
303.
Avram, Anca M
Patel, Vinod
Taylor, Harris C
Kirwan, John P
and
Kalhan, Satish
2001.
Euglycemic Clamp Study in Clozapine-Induced Diabetic Ketoacidosis.
Annals of Pharmacotherapy,
Vol. 35,
Issue. 11,
p.
1381.
Chae, Beang‐Jin
and
Kang, Byung‐Jo
2001.
The effect of clozapine on blood glucose metabolism.
Human Psychopharmacology: Clinical and Experimental,
Vol. 16,
Issue. 3,
p.
265.
Liebzeit, Krystal A.
Markowitz, John S.
and
Caley, Charles F.
2001.
New onset diabetes and atypical antipsychotics.
European Neuropsychopharmacology,
Vol. 11,
Issue. 1,
p.
25.
Koller, Elizabeth
Schneider, Bruce
Bennett, Katherine
and
Dubitsky, Greg
2001.
Clozapine-associated diabetes.
The American Journal of Medicine,
Vol. 111,
Issue. 9,
p.
716.
Shiloah, Eli
Witz, Shula
Abramovitch, Yehuda
Cohen, Ohad
Buchs, Andreas
Ramot, Yoram
Weiss, Mordechai
Unger, Abraham
and
Rapoport, Micha J.
2003.
Effect of Acute Psychotic Stress in Nondiabetic Subjects on β-Cell Function and Insulin Sensitivity .
Diabetes Care,
Vol. 26,
Issue. 5,
p.
1462.
Fuller, Matthew A.
Shermock, Kenneth M.
Secic, Michelle
and
Grogg, Amy L.
2003.
Comparative Study of the Development of Diabetes Mellitus in Patients Taking Risperidone and Olanzapine.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,
Vol. 23,
Issue. 8,
p.
1037.
Clark, Clifford
and
Burge, Mark R.
2003.
Diabetes Mellitus Associated with Atypical Anti-Psychotic Medications.
Diabetes Technology & Therapeutics,
Vol. 5,
Issue. 4,
p.
669.
Melkersson, Kristina
and
Dahl, Marja-Liisa
2004.
Adverse Metabolic Effects Associated with Atypical Antipsychotics.
Drugs,
Vol. 64,
Issue. 7,
p.
701.
Schwenkreis, Peter
and
Assion, Hans-jörg
2004.
Atypical antipsychotics and diabetes mellitus.
The World Journal of Biological Psychiatry,
Vol. 5,
Issue. 2,
p.
73.
Ananth, Jambur
and
Kolli, Smita
2005.
Atypical antipsychotic agents and increased risk of diabetes: class action or differential action?.
Expert Opinion on Drug Safety,
Vol. 4,
Issue. 1,
p.
55.
Newcomer, John W.
2005.
Second-Generation (Atypical) Antipsychotics and Metabolic Effects.
CNS Drugs,
Vol. 19,
Issue. Supplement 1,
p.
1???93.
Engl, Julia
Tschoner, Alexander
Laimer, Markus
Rettenbacher, Maria
Wolfgang Fleischhacker, W.
Patsch, Josef R.
and
Ebenbichler, Christoph
2006.
Metabolische Nebenwirkungen von Antipsychotika der neuen Generation.
Wiener klinische Wochenschrift,
Vol. 118,
Issue. 7-8,
p.
196.
Holt, Richard I. G.
and
Peveler, Robert C.
2006.
Association between antipsychotic drugs and diabetes.
Diabetes, Obesity and Metabolism,
Vol. 8,
Issue. 2,
p.
125.
Tschoner, A.
Engl, J.
Laimer, M.
Kaser, S.
Rettenbacher, M.
Fleischhacker, W. W.
Patsch, J. R.
and
Ebenbichler, C. F.
2007.
Metabolic side effects of antipsychotic medication.
International Journal of Clinical Practice,
Vol. 61,
Issue. 8,
p.
1356.
Guenette, Melanie D.
Hahn, Margaret
Cohn, Tony A.
Teo, Celine
and
Remington, Gary J.
2013.
Atypical antipsychotics and diabetic ketoacidosis: a review.
Psychopharmacology,
Vol. 226,
Issue. 1,
p.
1.
Vuk, Antonia
Baretic, Maja
Osvatic, Martina Matovinovic
Filipcic, Igor
Jovanovic, Nikolina
and
Kuzman, Martina Rojnic
2017.
Treatment of Diabetic Ketoacidosis Associated With Antipsychotic Medication.
Journal of Clinical Psychopharmacology,
Vol. 37,
Issue. 5,
p.
584.
De Berardis, Domenico
Rapini, Gabriella
Olivieri, Luigi
Di Nicola, Domenico
Tomasetti, Carmine
Valchera, Alessandro
Fornaro, Michele
Di Fabio, Fabio
Perna, Giampaolo
Di Nicola, Marco
Serafini, Gianluca
Carano, Alessandro
Pompili, Maurizio
Vellante, Federica
Orsolini, Laura
Martinotti, Giovanni
and
Di Giannantonio, Massimo
2018.
Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.
Therapeutic Advances in Drug Safety,
Vol. 9,
Issue. 5,
p.
237.
eLetters
No eLetters have been published for this article.